ECM
ENGN icon

ExodusPoint Capital Management’s enGene Therapeutics ENGN Stock Holding History

ExodusPoint Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,613
Closed -$181K – 1697
2026
Q1 		$181K Buy
+26,613
New +$237K ﹤0.01% 1391

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

ExodusPoint Capital Management's ENGN Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 26,613 shares — an estimated $181K sold.

ExodusPoint Capital Management first reported a position in ENGN in Q1 2026 and held it in 1 quarter. The position peaked at $181K in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • ExodusPoint Capital Management reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 26,613 enGene Therapeutics shares in Q2 2026, an estimated $181K.
  • ExodusPoint Capital Management first reported a position in enGene Therapeutics in Q1 2026 and held it in 1 quarter.
  • ExodusPoint Capital Management's enGene Therapeutics position peaked at $181K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.